0001562180-20-005777.txt : 20200902
0001562180-20-005777.hdr.sgml : 20200902
20200902200143
ACCESSION NUMBER: 0001562180-20-005777
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200831
FILED AS OF DATE: 20200902
DATE AS OF CHANGE: 20200902
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: THERO JOHN F
CENTRAL INDEX KEY: 0001199637
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-21392
FILM NUMBER: 201158072
MAIL ADDRESS:
STREET 1: C/O AMARIN PHARMA, INC.
STREET 2: 1430 ROUTE 6
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMARIN CORP PLC\UK
CENTRAL INDEX KEY: 0000897448
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: X0
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: SPACES SOUTH DOCKLANDS, BLOCK C
STREET 2: 77 SIR JOHN ROGERSON'S QUAY
CITY: DUBLIN 2
STATE: L2
ZIP: D02 VK60
BUSINESS PHONE: 353 1 6699 020
MAIL ADDRESS:
STREET 1: SPACES SOUTH DOCKLANDS, BLOCK C
STREET 2: 77 SIR JOHN ROGERSON'S QUAY
CITY: DUBLIN 2
STATE: L2
ZIP: D02 VK60
FORMER COMPANY:
FORMER CONFORMED NAME: AMARIN PHARMACEUTICALS PLC
DATE OF NAME CHANGE: 20000201
FORMER COMPANY:
FORMER CONFORMED NAME: ETHICAL HOLDINGS PLC
DATE OF NAME CHANGE: 19930322
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2020-08-31
false
0000897448
AMARIN CORP PLC\UK
AMRN
0001199637
THERO JOHN F
C/O AMARIN PHARMA, INC.
440 US HIGHWAY 22
BRIDGEWATER
NJ
08807
true
true
false
false
President and CEO
Ordinary Shares
2020-08-31
4
M
false
6736.00
A
2528025.00
D
Ordinary Shares
2020-08-31
4
M
false
6736.00
A
2534761.00
D
Ordinary Shares
2020-08-31
4
F
false
5302.00
7.36
D
2529459.00
D
Restricted Stock Units
0.00
2020-08-31
4
M
false
6736.00
0.00
D
Ordinary Shares
6736.00
80833.00
D
Restricted Stock Units
0.00
2020-08-31
4
M
false
6736.00
0.00
D
Ordinary Shares
6736.00
80833.00
D
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
As previously reported on February 27, 2020, on May 15, 2017, the Reporting Person was granted 970,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc Stock Incentive Plan (the "Plan"), of which the performance criteria related to two tranches representing 50% of the total award was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued employment of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The twenty-fourth vesting event occurred on August 31, 2020. The performance criteria related to the remaining 50% tranche has not yet been achieved; such tranche has not lapsed as a result of achieving the other two tranches.
Not applicable.
Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities.
Please see the section titled "Remarks" below for additional information.
Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion.
As of the date of this Form 4, the Reporting Person owns or holds the right to acquire an aggregate of 9,524,590 Ordinary Shares of the Issuer in the form of Ordinary Shares, stock options and RSUs granted under the Plan, including but not limited to certain performance-based RSUs that are earned only if product revenues reach pre-defined annual milestone levels and, in certain cases, then vest only if the recipient remains with the company for an extended period of time.
/s/ John F. Thero
2020-09-02